• June 2023
  Biomissile Announces First Subject Successfully Dosed in Phase 1 Trial of BM012 (HT-102)
  Read More
• June 2023
  First Subject Successfully Dosed in Phase 1 Trial of BM219
  Read More
• May 2023
  Biomissile closed Series B fundraising of ￥200M (CNY) to advance its UDAB^TM and UDAB-M^TM therapeutic pipeline
  Read More
• December 2022
  Future Unicorn Accolade of Jiangsu Province
  Read More
• October 2022
  Towards the functional cure of HBV, BM012 pre-IND submitted
  Read More
• March 2022
  Preclinical data of BM219, an inhalable bispecific UDAB with broad neutralization of SARS-CoV-2 variants, was published in Cell
  Read More